Related Experiment Videos
Gene therapy for pediatric brain tumors
1Department of Pediatrics, University of Florida College of Medicine, Gainesville, USA.
Seminars in Pediatric Neurology
|February 3, 1998
Summary
Gene therapy, specifically suicide gene therapy using the herpes virus thymidine kinase (HSV-TK) gene, offers a promising approach for treating malignant brain tumors like gliomas. This method leverages the "bystander effect" to eliminate more tumor cells than are directly modified.
Area of Science:
- Oncology
- Gene Therapy
- Neuro-oncology
Background:
- Malignant brain tumors, such as gliomas, have a poor prognosis despite advances in conventional cancer treatments.
- Gene therapy presents a novel strategy to target cancer by correcting genetic defects, boosting immune responses, or sensitizing tumor cells.
Purpose of the Study:
- To explore the potential of suicide gene therapy as a treatment for malignant brain tumors.
- To investigate the mechanism and efficacy of the herpes simplex virus thymidine kinase (HSV-TK) suicide gene therapy in gliomas.
Main Methods:
- Insertion of the herpes virus thymidine kinase (HSV-TK) gene into glioma cells.
- Administration of ganciclovir to sensitize genetically modified tumor cells.
- Experimental investigation of the "bystander effect" requiring gap junctions and immunocompetence.
Main Results:
- The HSV-TK gene therapy strategy sensitizes glioma cells to ganciclovir, leading to tumor cell death.
- The "bystander effect" demonstrates that genetically modified cells can induce the death of neighboring tumor cells, enhancing therapeutic impact.
Conclusions:
- Suicide gene therapy, particularly the HSV-TK/ganciclovir system, shows promise for treating gliomas, with ongoing clinical trials.
- Challenges remain in neuro-oncology, including optimizing the "bystander effect" and developing feasible p53 gene replacement and immunomodulatory strategies.